Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia.
Expert Rev Neurother. 2011 Sep;11(9):1305-13. doi: 10.1586/ern.11.114.
Guillain-Barré syndrome (GBS) is typically classified into two major subtypes: acute inflammatory demyelinating neuropathy and acute motor axonal neuropathy. Its most recognizable variant is Fisher syndrome. The last two decades have seen considerable advances in our understanding of GBS. Of note, various autoantibodies against ganglioside antigens have been identified and found to have significant associations with the axonal forms of GBS and Fisher syndrome. In this article, we discuss the different clinical presentations in GBS and the role of antiganglioside antibodies in their underlying pathogenesis. We also discuss the impact that antiganglioside antibodies have had in the development of experimental models and treatment modalities in GBS.
格林-巴利综合征(GBS)通常分为两种主要亚型:急性炎症性脱髓鞘性多发性神经病和急性运动轴索性神经病。其最易识别的变异型是 Fisher 综合征。在过去的二十年中,我们对 GBS 的认识有了相当大的进展。值得注意的是,已经鉴定出针对神经节苷脂抗原的各种自身抗体,并发现它们与 GBS 和 Fisher 综合征的轴索性形式有显著关联。在本文中,我们讨论了 GBS 的不同临床表现以及神经节苷脂抗体在其潜在发病机制中的作用。我们还讨论了神经节苷脂抗体在 GBS 实验模型和治疗方式的发展中的影响。